Novartis aims to hold itself to the highest standards of sustainability and ethical business practices. Our performance against environmental, social and governance (ESG) criteria is reflected in various third-party ratings.

Download a summary of our ESG ratings performance (PDF 0.2 MB).

Industry-leading performance across priority ESG ratings

Rating Score1 Position / Status
Access to Medicine Index (ATMI) 3.87 4th (in the leadership group for 10 years)
CDP Climate Change A Double A List
CDP Water Security A
ISS ESG B Leader status
MSCI AA Leader status
S&P Global 84 4th (98th percentile)
Sustainalytics* 16.9 Low Risk category

For more information on our awards and recognition, please click here.

Last update: February 2023

1. Scales: ATMI: 1 to 5; CDP: D- to A; ISS ESG: D- to A+ ; MSCI: CCC to AAA; S&P Global: 0 to 100; Sustainalytics ESG Risk Rating: 0 (Negligible risk) to 40+ (Severe risk)

* Copyright © 2023 Morningstar Sustainalytics. All rights reserved. This publication contains information developed by Sustainalytics (www.sustainalytics.com). Such information and data are proprietary of Sustainalytics and/or its third-party suppliers (Third Party Data) and are provided for informational purposes only. They do not constitute an endorsement of any product or project, nor an investment advice and are not warranted to be complete, timely, accurate or suitable for a particular purpose. Their use is subject to conditions available at https://www.sustainalytics.com/legal-disclaimers.